With telaglenastat facing a risky trial readout Calithera picks up two bargain-basement oncology projects to pivot to.
After the Valor defeat, the group and its partner Biogen will hope that going earlier could improve the amyotrophic lateral sclerosis project’s chances.
The group’s Covid-19 vaccine is on course for UK approval – but the UK doesn’t want it.
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
But a potentially more interesting advisory committee, for Merck and Ridgeback’s molnupiravir, awaits.
Crispr follows Allogene with backing for off-the-shelf Car-T therapy – and adds big concerns over lack of durability.
The company’s off-the-shelf T-cell immunotherapy seems to be improving multile sclerosis disability, but an ongoing phase 2 trial will provide a better test.